ZLAB   $27.5  4.32% Market Closed After Close 27.25 -0.91%

Zai Lab Ltd
Last Events:

2023-08-09 Signal in Stochastic changed from bearish to bearish weakening. The stochastic indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-09 Trend Power changed from almost flat to slow.

2023-08-06 Signal in MACD changed from bearish reversal to bearish. Oscillator MACD is in the negative territory it's lower than the signal line and it crossed the zero line from the top. These factors mean that there is probably a falling trend. Last signal: down-crossing the middle level.

2023-08-06 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-05 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-04 Signal in MACD changed from bullish weakening to bearish reversal. Oscillator MACD is in the positive territory it crossed the signal line from the top and falls. These factors mean that the market confirms the end of the upward trend. Last signal: main and signal line crossing.

2023-08-03 Signal in RSI changed from bullish weakening to bearish. RSI indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: entrance to the overbought zone.

2023-08-03 Signal in EMA50 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.


Current temperature: 8.12
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 10
Target Price Mean 49.82
Mean unverified/preliminary 49.82 / 49.82
Target Price Low / High 25.00 / 66.00
Median / STD DEV 54.23 / 14.26
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy ActivelyBuy None
rsi Sell ActivelyBuy Sell
macd None None None
stoch None None None
ma20 ActivelyBuy Buy ActivelyBuy
ma50 None None None
ma100 Buy ActivelyBuy ActivelyBuy
Candlestick PatternOct. 18, 2024 Three Soldiers - is a candlestick pattern that consists of three long white candlesticks with consecutively higher closes. The closing prices are near to or at their highs. Considered to be a bullish reversal pattern.
ISIN US98887Q1040
ceo Dr. Ying Du Ph.D.
Website https://www.zailaboratory.com
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.